Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma

References

• Clifford GM, Rickenbach M, Lise M, . Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009;113:5737–5742.
   PubMed Web of Science ®Google Scholar
• Biggar RJ, Jaffe ES, Goedert JJ, . Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006;108: 3786–3791.
   PubMed Web of Science ®Google Scholar
• Franceschi S, Lise M, Clifford GM, . Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010;103:416–422.
   PubMed Web of Science ®Google Scholar
• Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011;117:1089–1096.
   PubMed Web of Science ®Google Scholar
• Ezzat H, Filipenko D, Vickars L, . Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy. HIV Clin Trials 2007;8:132–144.
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, . Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15: 1483–1491.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Ribera JM, Oriol A, . Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone. Br J Haematol 2001;112:909–915.
   PubMed Web of Science ®Google Scholar
• Levine AM, Li P, Cheung T, . Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149). J Acquir Immune Defic Syndr 2000;24:444–450.
   PubMed Web of Science ®Google Scholar
• Hoffmann C, Chow KU, Wolf E, . Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease. Br J Haematol 2004;125:455–462.
   PubMed Web of Science ®Google Scholar
• Xicoy B, Ribera JM, Miralles P, . Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007;92:191–198.
   PubMed Web of Science ®Google Scholar
• Chemotherapy protocols. Lymphoma & myeloma [Internet]. Available from: http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols
   Google Scholar
• Yao D, Ding S, Burchell B, . Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J Pharmacol Exp Ther 2000;294: 387–395.
   PubMed Web of Science ®Google Scholar
• Zhou-Pan XR, Seree E, Zhou XJ, . Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res 1993;53:5121–5126.
   PubMed Web of Science ®Google Scholar
• Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res 1977;37:2597–2602.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Hicks LK, Leitch HA. Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:E22–E25.
   Google Scholar
• Stein H. Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, ., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008. pp. 321–334.
   Google Scholar
• Duggan DB, Petroni GR, Johnson JL, . Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607–614.
   PubMed Web of Science ®Google Scholar
• NCI Common Toxicity Criteria [Internet]. Available from: http://evs.nci.hih.gov/ftpi/CTCAE/CTCAE_4.03_2010-06-14
   Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005;10:412–426.
   PubMed Web of Science ®Google Scholar
• Holkova B, Takeshita K, Cheng DM, . Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol 2001;19:3848–3851.
   PubMed Web of Science ®Google Scholar
• Besson C, Goubar A, Gabarre J, . Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood 2001;98:2339–2344.
   PubMed Web of Science ®Google Scholar
• Chow KU, Mitrou PS, Geduldig K, . Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2001;41:105–116.
   PubMed Web of Science ®Google Scholar
• Kirk O, Pedersen C, Cozzi-Lepri A, . Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood 2001;98:3406–3412.
   PubMed Web of Science ®Google Scholar
• Matthews GV, Bower M, Mandalia S, . Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy. Blood 2000;96:2730–2734.
   PubMed Web of Science ®Google Scholar
• Navarro JT, Ribera JM, Oriol A, . Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2003;32: 347–348.
   PubMed Web of Science ®Google Scholar
• Vaccher E, Spina M, Talamini R, . Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clin Infect Dis 2003;37:1556–1564.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, . Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992;327:1478–1484.
   PubMed Web of Science ®Google Scholar
• Kotb R, Vincent I, Dulioust A, . Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006; 76:269–271.
   PubMed Web of Science ®Google Scholar
• Makinson A, Martelli N, Peyriere H, . Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 2007;78:358–360.
   PubMed Web of Science ®Google Scholar
• Martin P, Leonard JP, Coleman M, . Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsis. Clin Lymphoma Myeloma 2009;9:247–249.
   PubMedGoogle Scholar
• Cingolani A, Torti L, Pinnetti C, . Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastine in HIV-infected patients with Hodgkin's lymphoma. AIDS 2010;24:2408–2412.
   PubMed Web of Science ®Google Scholar
• Drewe J, Gutmann H, Fricker G, . HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 1999;57:1147–1152.
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, . Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol 2005;23:7614–7620.
   PubMed Web of Science ®Google Scholar
• O’Sullivan JM, Huddart RA, Norman AR, . Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003;14:91–96.
   PubMed Web of Science ®Google Scholar
• Simpson AB, Paul J, Graham J, . Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998;78:1061–1066.
   PubMed Web of Science ®Google Scholar
• Blum RH, Carter SK, Agre K. A clinical review of bleomycin— a new antineoplastic agent. Cancer 1973;31:903–914.
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, . Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS 2001;15: 1483–1491.
   PubMed Web of Science ®Google Scholar